600056 中国医药
2025/12 -
人民幣(K¥)

变动
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入35,361,6220.34%38,824,43137,592,65036,234,41539,311,753
减:营业总成本34,112,3880.27%37,501,89536,137,94034,480,96436,386,460
    其中:营业成本31,647,8470.60%34,440,81432,845,78631,018,23932,512,228
               财务费用110,016-47.98%112,038138,317221,691257,359
               资产减值损失(150,704)-16.46%(13,539)(280,660)(575,297)(682,774)
公允价值变动收益(2,211)-101.73%9851,922(2,135)656
投资收益(68,010)6.15%(15,792)51,00143,65737,514
    其中:对联营企业和合营企业的投资收益31,36767.42%77,04393,219113,90088,306
营业利润1,022,9883.69%1,672,3341,199,698937,1351,939,187
利润总额999,295-0.88%1,640,5561,196,127940,1061,925,266
减:所得税费用324,65918.34%398,435307,699225,830539,186
净利润674,636-8.06%1,242,120888,428714,2761,386,081
减:非控股权益201,40733.18%194,081152,82767,21975,435
股东净利润473,229-18.77%1,048,039735,601647,0571,310,646

市场价值指针
每股收益 (元) *0.316-18.77%0.7010.4920.4331.227
每股派息 (元) *0.095-11.62%0.2100.1480.1820.368
每股净资产 (元) *7.9120.13%7.7287.230--9.364
审计意见 #标准无保留意见标准无保留意见标准无保留意见标准无保留意见--
回页顶
备注: *未调整数据
#只提供简体内容